Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide in ASCVD and/or CKD with BMI ≥27
NCT06383390Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Primary completion
- Feb 2029
- Modality
- Peptides, Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of retatrutide in atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), sponsored by Eli Lilly and Company. Started Apr 2024; status: active, not recruiting.
02
Drugs
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06383390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383390.